Figures & data
Table 1 Correlations between clinicopathological parameters and FOXP1 expression in neoplastic and stromal compartments of primary tumor
Table 2 Correlations between histological characteristics of melanoma primary tumors and FOXP1 expression in neoplastic and stromal compartments
Figure 1 FOXP1 expression in skin melanoma patients.
Notes: (A) Normal skin without FOXP1 immunoreactivity (200×, hematoxylin). (B) Intermediate expression of FOXP1 in the basal epidermal cells and normal melanocytes with lack of immunoreactivity in nests of benign melanocytes in intradermal skin nevus. Note the moderate reaction in macrophages and fibroblasts (200×, hematoxylin). (C) Diffuse, strong FOXP1 reactivity in stromal cells (predominantly in tumor-associated macrophages) with lack of expression in malignant melanocytes; inset: immunohistochemical reaction (red chromogen) with anti-CD68 antibody (200×, 600×, hematoxylin). (D) Enhanced FOXP1 expression in stromal cells with low immunoreactivity in melanoma cells (200×, hematoxylin). (E) High FOXP1 expression in neoplastic melanocytes, higher magnification: FOXP1-positive melanoma cells with atypical mitotic figure (200×, 600×, hematoxylin). (F) Diffuse, strong FOXP1 reactivity in melanoma cells with lack of expression in stromal compartment (200×, hematoxylin).
Figure 2 Kaplan–Meier analysis of the prognostic impact of FOXP1 expression in cutaneous melanoma patients.
Notes: Upregulation of FOXP1 in melanoma cells was significantly associated with shorter CSOS and DFS (A and B, respectively). Elevated numbers of FOXP1-positive stromal cells had no significant impact on CSOS and DFS (C and D, respectively).
Abbreviations: CSOS, cancer-specific overall survival; DFS, disease-free survival.
Abbreviations: CSOS, cancer-specific overall survival; DFS, disease-free survival.
Table 3 Multivariable Cox regression analysis